Vera Therapeutics, Inc.

Vera Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing transformative treatments for patients suffering from serious immunological diseases. The company's mission is to advance therapies that target the underlying cause of disease, aiming to establish new standards of care. Headquartered in Brisbane, California, Vera Therapeutics focuses on addressing significant unmet medical needs in autoimmune conditions.

The company's lead product candidate is atacicept, a fusion protein designed for self-administration as a once-weekly subcutaneous injection. Atacicept functions by blocking both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which are key factors that stimulate B cells and plasma cells to produce autoantibodies implicated in various autoimmune diseases. Vera Therapeutics is primarily focused on developing atacicept for IgA nephropathy (IgAN), and is also evaluating its potential for other autoimmune kidney diseases, including lupus nephritis, focal segmental glomerulosclerosis (FSGS), and anti-PLA2R positive primary membranous nephropathy. The pipeline also includes VT-109, a next-generation BAFF/APRIL dual-inhibitor, and MAU868, a monoclonal antibody targeting BK virus infections, particularly relevant for kidney transplant recipients.

In recent developments, Vera Therapeutics announced positive Phase 3 data from the ORIGIN 3 study of atacicept in IgAN, which was presented at the American Society of Nephrology (ASN) and published in the New England Journal of Medicine. The U.S. Food and Drug Administration (FDA) has granted priority review for the Biologics License Application (BLA) for atacicept, with a Prescription Drug User Fee Act (PDUFA) target action date of July 7, 2026. A potential U.S. commercial launch for atacicept is anticipated in mid-2026, pending approval. The company maintains a strong financial position, expected to fund operations beyond the potential approval and commercial launch of atacicept. Marshall W. Fordyce, MD, serves as the Founder, President, and Chief Executive Officer, leading the company's strategic direction and development efforts.